All times listed are Central Standard Time (CST).

8:00 am – Welcome and Introductions
J. Allen Meadows, MD, FACAAI

8:03 am – If You're Not at the Table, You're Probably on the Menu!
Bill Finerfrock, President, Capitol Associates; Consultant, Advocacy Council of ACAAI

8:30 am – Keynote Presentation: Why "Value-based Payment" Isn't Working – And How Physicians Can Fix It
Harold D. Miller, President and CEO Center for Healthcare Quality and Payment Reform

9:20 am – Questions and Discussion

9:30 am – Adjourn

Not For Credit

During this case-based presentation, an expert will review the role of Type 2 inflammation in asthma.

Presented by: Todd Mahr, MD

Supported by Sanofi Genzyme and Regeneron

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

This session will review our understanding of nasal polyps and discuss the medical and surgical management of specific endotypes, with a focus on biologic therapies.

Supported by an independent educational grant from Genentech

All times listed are Central Standard Time (CST).

Moderators: John B. Hagan, MD, FACAAI, and Puneet Shroff, MD, FACAAI

10:00 am – Welcome and Introductions
John B. Hagan, MD, FACAAI, and Puneet Shroff, MD, FACAAI

10:03 am – Description of Underlying Endotypes and Visible Phenotypes Associated With Nasal Polyps
Sandra Y. Lin, MD

10:30 am – Current Approach to Medical and Surgical Management of Nasal Polyps
Joshua Levy, MD

10:55 am – The Use of Biologics in Nasal Polyps Based on Disease Mechanism of Individual Phenotypes
Merin E. Kuruvilla, MD

11:20 am – Questions and Discussion

11:30 am – Adjourn

Immunoglobulin replacement can be effective at preventing infection and treating certain inflammatory disorders. However, treatment is often complicated by adverse reactions. Multiple gamma globulin products are currently available, and choosing the best product for the individual patient can decrease the burden of treatment and improve adherence to this therapy.

Supported in part by an independent educational grant from CSL Behring

All times listed are Central Standard Time (CST).

Moderators: Purvi S.Parikh, MD, FACAAI, and Lisa J. Kobrynski, MD, MPH, FACAAI

10:00 am – Welcome and Introductions
Purvi S. Parikh, MD, FACAAI, and Lisa J. Kobrynski, MD, MPH, FACAAI

10:03 am – Immunoglobulin Replacement: The Proper Indications for Starting Therapy and Continuing Therapy
Vivian P. Hernandez-Trujillo, MD, FACAAI

10:40 am – Immunoglobulin Replacement: Pearls for Managing Antibody Deficient Patients on Immunoglobulin Replacement Therapy
Mark M. Ballow, MD, FACAAI

11:20 am – Questions and Discussion (Online Chat)

11:30 am – Adjourn

We now have multiple options available for patients with peanut allergy. This session will discuss how to use shared decision-making to help patients understand treatment options and help allergists understand what their patients value.

All times listed are Central Standard Time (CST).

Moderators: David R. Stukus, MD, FACAAI, and David M. Fleischer, MD, FACAAI

10:00 am – Welcome and Introductions
David R. Stukus, MD, FACAAI, and David M. Fleischer, MD, FACAAI

10:03 am – Non-FDA-Approved Oral Immunotherapy
Arnon Elizur, MD

10:20 am – FDA-Approved Oral Immunotherapy
Edwin H. Kim, MD, FACAAI

10:35 am – Epicutaneous Immunotherapy
Julie Wang, MD, FACAAI

10:50 am – Ongoing Avoidance Without Treatment
Jay A. Lieberman, MD, FACAAI

11:05 am – Using Shared Decision-making to Guide Patients Through the Options
Matthew C. Greenhawt, MD, MSc, MBA, FACAAI

11:20 am – Questions and Discussion

11:30 am – Adjourn

Each of the 7 presenters will have only 11 minutes to deliver insightful, targeted and dynamic information on their assigned topics.

All times listed are Central Standard Time (CST).

Moderator: Todd A. Mahr, MD, FACAAI

10:00 am – Welcome and Introductions
Todd A. Mahr, MD, FACAAI

10:05 am – Asthma
Angela D. Hogan, MD, FACAAI

10:16 am – Food Allergy – Non-treatment
J. Wesley Sublett, MD, MPH, FACAAI

10:27 am – Food Allergy – Treatment
J. Andrew Bird, MD, FACAAI

10:38 am – Biologics
Carla M. Davis, MD, FACAAI

10:49 am – Anaphylaxis
Julie Wang, MD, FACAAI

11:00 am – Immunology
Mary Beth Fasano, MD, MSPH, FACAAI

11:11 am – Epidemiology
Ruchi Gupta, MD, MPH

11:30 am – Adjourn

Dr. Gary Gross will review allergy & immunology billing coding updates and new codes for 2021, including the new E&M changes effective January 1.

All times listed are Central Standard Time (CST).

Moderator: Thomas J. Derrico

10:00 am – Welcome and Introductions
Thomas J. Derrico

10:10 am – Coding/Billing/Regulatory Update
Gary N. Gross, MD, FACAAI

11:00 am – ACAAI College Resources To Help Your Practice
Jennifer Pfeifer, MBA, CMPE

11:10 am – Questions and Discussion (Online Chat)

11:30 am – Adjourn

Not For Credit

Eosinophils are well recognized as having important roles in immune-mediated disorders. Our program will review the immunomodulatory role of eosinophils in health and disease and their involvement in severe asthma (and potential co-morbidities) and hypereosinophilic disorders. The importance of biomarkers in the evaluation of eosinophilic disorders will also be highlighted.

Presented by: Charlene Prazma, PhD, Chair; Steven J. Ackerman, PhD; Jonathan Corren, MD; and Princess Ogbogu, MD

Supported by GSK

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

Peanut allergy can significantly impact patients’ lives. With PALFORZIA now available, you can provide your patients with the first FDA-approved treatment for peanut allergy. Please join Dareen Siri, MD, and Ananth Thyagarajan, MD, as they review the clinical safety and efficacy of PALFORZIA and share their treatment experience.

Presented by: Dareen Siri, MD, and Ananth Thyagarajan, MD

Supported by Aimmune Therapeutics

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

Rediscover prevention in this dynamic program featuring data that shows what attack prevention can mean for your patients with HAE. Expert faculty will guide you through clinical data, including our new open-label extension study data, and a patient ambassador will bring the data to life by sharing her individual treatment experience.

Presented by: Marc Riedl, MD, and Andrea, Patient Ambassador

Supported by Takeda Pharmaceutical Company Limited

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

All times listed are Central Standard Time (CST).

Moderator: Brian T. Kelly, MD, MA, FACAAI

1:00 pm – Welcome and Introductions
Brian T. Kelly, MD, MA, FACAAI

1:03 pm – How Best to Battle the Infodemic
Timothy Caulfield, LLM, FRSC, FCAHS

1:25 pm – Immunology, Risk Factors, and Treatment of COVID-19
Brian Lipworth, MD, FACAAI

1:50 pm – Learning To Live with COVID-19: Strategies To Help Medical Professionals and Our Patients
Jessi Gold, MD, MS

2:15 pm – Questions and Discussion

2:30 pm – Adjourn

First, learn to improve efficiency and workflow in your practice using Lean Six Sigma. Then, learn how to address common legal issues facing A/I practices.

All times listed are Central Standard Time (CST).

Moderator: Thomas J. Derrico

1:00 pm – Welcome and Introductions
Thomas J. Derrico

1:03 pm – Practice Efficiency: Work Flow/Lean Six Sigma
Michael Tankersley, MD, MBA, FACAAI

1:35 pm – Legal Issues in Practice
Denise Yarborough, JD, Esq.

2:20 pm – Questions and Discussion (Online Chat)

2:30 pm – Adjourn

This session will review dysfunctional breathing in children and adults. Various aspects of the upper airway will be discussed, including how allergists can help identify and treat patients who have obstructive sleep apnea and exercise-induced laryngeal obstruction.

All times listed are Central Standard Time (CST).

Moderators: Jeremy S. Katcher, MD, FACAAI, and Michael R. Rupp, MD, FACAAI

1:00 pm – Welcome and Introductions
Jeremy S. Katcher, MD, FACAAI, and Michael R. Rupp, MD, FACAAI

1:03 pm – Obstructive Sleep Apnea: More Than Snoring – Allergists Can Help
Timothy J. Craig, DO, FACAAI

1:30 pm – Diagnosing Exercise-induced Laryngeal Obstruction and Dysfunctional Breathing
James Tod Olin, MD, MSCS

2:00 pm – Advances in Treatment and Behavioral Interventions To Treat EILO
Monica Shaffer, MA, CCC-SLP

2:30 pm – Adjourn

From basic science to the clinical conundrums, this session will cover how to evaluate and manage patients with contact dermatitis.

All times listed are Central Standard Time (CST).

Moderators: Sandra M. Gawchik, DO, FACAAI, and Tammy Peng, MD

1:00 pm – Welcome and Introductions
Sandra M. Gawchik, DO, FACAAI, and Tammy Peng, MD

1:03 pm – Interpretation of Skin Biopsy Results in Eczema
Whitney A. High, MD, MEng

1:28 pm – Clinical Pearls and Pitfalls in Evaluating Patients With Contact Dermatitis
Sharon E. Jacob, MD

1:53 pm – How To Help Patients With Contact Dermatitis Before and After Patch Testing
Jeff J. Yu, MD

2:20 pm – Questions and Discussion (Online Chat)

2:30 pm – Adjourn

While we currently have 19 standardized subcutaneous allergens in the United States, there are several different methods used to describe standardized allergens. In Europe there are standardization terms that are unfamiliar to many U.S. allergists. It is important for the practicing allergist to understand the methodologies for the standardization of allergen extracts and how the standardized allergens may influence clinical allergen immunotherapy in the U.S.

All times listed are Central Standard Time (CST).

Moderators: Ellen R. Sher MD, FACAAI, and Peter J. Mustillo, MD, FACAAI

1:00 pm – Welcome and Introductions
Ellen R. Sher MD, FACAAI, and Peter J. Mustillo, MD, FACAAI

1:03 pm – Are You Dosing Properly?
Harold S. Nelson, MD, FACAAI 

1:30 pm – Do Patients Receiving Subcutaneous Immunotherapy Need To Have an Epinephrine Auto-injector Prescribed?
David I. Bernstein, MD, FACAAI 

1:55 pm – Ultra-rush, Rush and Standard Build-up Dosing: Who? When? Why? Where? And How?
Jay M. Portnoy, MD, FACAAI

2:20 pm – Questions and Discussion

2:30 pm – Adjourn

Not For Credit

A non-CME disease state presentation focusing on nasal polyposis. Topics include: characteristics of nasal polyps, pathophysiology, common comorbid conditions, the role of type 2 inflammation in nasal polyposis, and the importance of an integrated multidisciplinary approach for optimal management.

Presented by: Tara F. Carr, MD

Supported by Novartis Pharmaceuticals Corporation

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

During this case-based presentation, an expert will review the role of Type 2 inflammation in asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis.

Presented by: Ujwala Kaza, MD

Supported by Sanofi Genzyme and Regeneron

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

This session will discuss how allergists can understand racial and ethnic disparities and address these issues with respect to caring for patients with food allergy, asthma and atopic dermatitis.

All times listed are Central Standard Time (CST).

Moderator: David R. Stukus, MD, FACAAI

3:00 pm – Welcome and Introductions
David R. Stukus, MD, FACAAI

3:03 pm – Atopic Dermatitis Disparities
Jonathan Silverberg, MD, PhD, MPH

3:30 pm – Asthma Disparities
Tamara T. Perry, MD

3:55 pm – Food Allergy Disparities
Carla Davis, MD, FACAAI

4:20 pm – Questions and Discussion

4:30 pm – Adjourn

This session will discuss everything you wanted to know about pollen and molds. It will begin by reviewing pollen identification with seasonal and regional variations. Next, we'll go indoors and review how to perform a home assessment for allergens in the home. This session is designed for all healthcare workers in the field of allergy.

Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

Supported by an independent educational grant from Aimmune Therapeutics

All times listed are Central Standard Time (CST).

3:00 pm – Welcome and Introductions
Jodi A. Shroba, MSN, APRN, CPNP

3:03 pm – Let's Take It Outside: A Review of Pollens and Molds
Amanda L. Michaud, PA-C

3:45 pm – Bringing It Home: How To Perform a Home Assessment
Kevin Kennedy, MPH, CIEC

4:30 pm – Adjourn

First, get an update on the current telemedicine landscape and how to optimize telemedicine in practice. Next, learn how to recognize, assess and mitigate cybersecurity risk.

All times listed are Central Standard Time (CST).

Moderator: Thomas J. Derrico

3:00 pm – Welcome and Introductions
Thomas J. Derrico

3:03 pm – Telehealth in Private Practice: Optimizing and Enhancing for the Future
Tania Elliott, MD, FACAAI

3:45 pm – Cyber Security: Recognizing, Assessing and Mitigating Risks
Joseph Alessi

4:30 pm – Adjourn

Chronic rhinosinusitis is a common condition impacting millions of patients. This session will discuss the common causes and contributing factors that allergists should consider during evaluation. In addition, various medical and surgical treatment approaches will be discussed, including how to discuss and choose the best options for each individual patient.

All times listed are Central Standard Time (CST).

Moderator: J. Wesley Sublett, MD, MPH, FACAAI

3:00 pm – Welcome and Introductions
J. Wesley Sublett, MD, MPH, FACAAI

3:03 pm – Causes, Contributing Factors and Evaluation of the Patient
Jonathan A. Bernstein, MD, FACAAI

3:30 pm – Medical Therapies
Whitney Stevens, MD, PhD

4:00 pm – Today's Surgical Options and Outcomes
Thomas S. Higgins, MD, MSPH

4:30 pm – Adjourn

Infants present with different signs and symptoms of anaphylaxis, as compared to older patients. Attendees will be able to identify anaphylaxis in infants and educate the parents/ family members of these infants. Proper management and treatment will also be reviewed.

All times listed are Central Standard Time (CST).

Moderators: Michael Pistiner, MD, MMSc, FACAAI, and Kristin C. Sokol, MD, MS, MPH, FACAAI

3:00 pm – Welcome and Introductions
Michael Pistiner, MD, MMSc, FACAAI, and Kristin C. Sokol, MD, MS, MPH, FACAAI

3:03 pm – Epidemiology and Presentation of Infant Anaphylaxis – Signs and Symptoms
Vivian P. Hernandez-Trujillo, MD, FACAAI

3:30 pm – Treatment and Management of Infant Anaphylaxis
Jay A. Lieberman, MD, FACAAI 

3:55 pm – Infants in the Office Setting: Practical Aspects of Early Peanut Introduction and Oral Food Challenges
Justin Greiwe, MD, FACAAI

4:20 pm – Questions and Discussion (Online Chat)

4:30 pm – Adjourn

Recent events, including an unprecedented global pandemic and the 2019 measles outbreak, highlight the importance of universal vaccination.

However, parents of young children do not always comply with recommended vaccinations for various reasons, including fear of vaccine-related adverse reaction. Allergists/immunologists can play an important role in improving vaccination rates by dispelling unfounded fears, evaluating patients with suspected adverse reactions and assessing risk in patients with severe allergy to vaccine ingredients.

All times listed are Central Standard Time (CST).

Moderators: Melinda M. Rathkopf, MD, FACAAI, and Mervat Nassef, MD, FACAAI 

3:00 pm – Welcome and Introductions
Melinda M. Rathkopf, MD, FACAAI, and Mervat Nassef, MD, FACAAI

3:03 pm – Lessons Learned From Recent Outbreaks and How To Deal With Vaccine Hesitancy
Lisa Saiman, MD, MPH 

3:30 pm – Evaluation and Management of Adverse Reactions to Vaccines
John M. Kelso, MD, FACAAI

3:55 pm – Vaccine Development: Why? When? How?
Julie E. Ledgerwood, DO

4:20 pm – Questions and Discussion

4:30 pm – Adjourn

All attendees are invited to participate in the College’s Annual House of Delegates Town Hall Meeting, Friday, November 13 at 4:30 pm CT. Learn about new resolutions and what telehealth will look like post COVID-19.

Speakers:
Curtis L. Hedberg, MD, FACAAI, Speaker of the ACAAI House of Delegates
Bill Finerfrock, President of Capitol Associates, Consultant to Advocacy Council of ACAAI

I. Welcome and Officer Introductions

II. Business Meeting

a. Approve Minutes

b. Recording Secretary and Super-delegate Voting

c. Resolutions

III. Introduction of State Delegates

IV. Summary of Regional Town Hall Meetings

V. What Will Telehealth Look Like Post COVID-19?     
    Bill Finerfrock

Not For Credit

All times listed are Central Standard Time (CST).

Moderator: Todd A, Mahr, MD, FACAAI

4:30 pm – Welcome and Introductions
Todd A, Mahr, MD, FACAAI

4:33 pm – Abrocitinib Versus Dupilumab: Time to Improvement by Body Region (JADE COMPARE)
Marjolein De Bruin-Weller, MD

4:43 pm – Ligelizumab Achieves Fast Control of Symptoms in More Patients With Chronic Spontaneous Urticaria Versus Omalizumab
Thomas Severin, MD

4:53 pm – Efficacy of Ligelizumab in Patients With Chronic Spontaneous Urticaria Inadequately Controlled With Omalizumab
Gordon Sussman, MD

5:03 pm – Berotralstat Reduces Attacks in Patients With Hereditary Angioedema (HAE): APeX-2 Trial 48 Week Results
H. James Wedner, MD

5:13 pm – Questions and Discussion

5:30 pm – Adjourn

Not For Credit

All times listed are Central Standard Time (CST).

Moderator: Melanie A. Ruffner, MD, PhD

4:30 pm – Welcome and Introductions
Melanie A. Ruffner, MD, PhD

4:33 pm – Development of an EHR-Based Algorithm To Identify Patients With Chronic Cough
Vishal Bali, MD

4:43 pm – Patients With Chronic Rhinosinusitis With and Without Asthma: A Real-world Experience
Hector Ortega, MD

4:53 pm – Continued Safety/Efficacy of Omalizumab in Chronic Rhinosinusitis With Nasal Polyps: An Open-label Extension Study
Philippe Gevaert, MD

5:03 pm – Questions and Discussion

5:30 pm – Adjourn

Not For Credit

Hear experts review Type 2 inflammation as a broad, underlying disease process. Our experts will review current literature on Type 2 cytokines, including IL-4 and IL-13, which contribute to epithelial barrier dysfunction, eosinophilic inflammation, and allergic inflammation

Presented by: William W. Busse, MD, and Samuel Louie, MD

Supported by Sanofi Genzyme and Regeneron

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

Join our multidisciplinary speakers as they walk us through their perspectives of the most recent diagnostic and management guidelines for Eosinophilic Esophagitis. Together they will define EoE, describe various manifestations of chronic esophageal inflammation, and explore diagnostic challenges and management approaches in the context of guideline recommendations.

Presented by: Jonathan Spergel, MD, PhD, and Ikuo Hirano, MD

Supported by Takeda Pharmaceuticals U.S.A., Inc.

These non-CME presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

Is there a novel way to think about asthma inflammation? Join a panel of leading experts to discuss 1) the central role of the airway epithelium and epithelial cytokines (alarmins) in asthma, and 2) the role of thymic stromal lymphopoietin (TSLP) as a key driver of multiple types of inflammation.

Presented by: Neal Jain, MD; Jonathan Corren, MD; and Anju Peters, MD

Supported by AstraZeneca and Amgen

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

Presented by: Mariana Castells, MD, PhD

Supported by Blueprint Medicines

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Previously thought to be two separate disease states, it is now widely accepted that some patients exhibit a mixed asthma and COPD presentation. This session will explore the diagnosis and management of this challenging patient population.

Educational credit for the Advanced Practice Health Care Providers Course is only available to those who pre-registered for it.

All times listed are Central Standard Time (CST).

Moderator: Jodi A. Shroba, MSN, APRN, CPNP

8:00 am – Welcome and Introductions
Jodi A. Shroba, MSN, APRN, CPNP

8:03 am – Asthma/COPD Overlap
Michelle R. Dickens, MSN, RN, FNP-C, AE-C

8:45 am – Adjourn

This plenary will provide dynamic presentations surrounding important topics that have evolved in recent years. Allergists are in a unique position to provide education to patients and help them understand their risk from various scenarios. The field of component diagnostic testing for food, inhalant and venom allergens has rapidly expanded, and attendees will learn how to utilize and interpret various tests. Attendees will also learn how to apply specialty training in allergy and immunology to address common concerns from patients regarding dermatologic conditions.

All times listed are Central Standard Time (CST).

Moderator: Mark L. Corbett, MD, FACAAI

8:00 am – Welcome and Introductions
Mark L. Corbett, MD, FACAAI

8:03 am – How To Discuss Complicated Concepts Surrounding Risk With Patients
Elissa M. Abrams, MD

8:25 am – Component-resolved Diagnostics – Which Ones Are Ready for Prime Time?
Giorgio Walter Canonica, MD

8:45 am – Edward J. O'Connell Lecture: Lessons Learned From the Skin: How Allergists Can Help Our Patients With Their Common Concerns
Luz S. Fonacier, MD, FACAAI

9:05 am – Bela Schick Lecture: Then, Now and Where Do We Go from Here?
James M. Tracy, DO, FACAAI

9:30 am – Adjourn

All times listed are Central Standard Time (CST).

Moderator: Lisa J. Kobrynski, MD, MPH, FACAAI

8:00 am – Welcome and Introductions
Lisa J. Kobrynski, MD, MPH, FACAAI

8:03 am – Lessons From Antibiotic Oral Challenges in 68 Pediatric Patients at a Tertiary Center
Grant Pickett, MD

8:18 am – Short-term Cardiac Outcomes: Aspirin Desensitization in Acute Coronary Syndrome
Amie Nguyen, MD

8:33 am – Diagnosis of Specific Antibody Deficiency (SAD): Comparison of Different Diagnostic Methods
Vivien Pat

8:48 am – Current Practice of Immunophenotyping Pre- and Post-rituximab Administration
Di Sun, MD, MPH

9:03 am – Questions and Discussion (Online Chat)

9:30 am – Adjourn

Supported by an independent educational grant from Merck

All times listed are Central Standard Time (CST).

Moderators: Alan B. Goldsobel, MD, FACAAI, and David R. Stukus, MD, FACAAI

8:00 am – Welcome and Introductions
Alan B. Goldsobel, MD, FACAAI and David R. Stukus, MD, FACAAI

8:03 am – Choosing the Proper Test From Your Diagnostic Tool Belt
Mandel R. Sher, MD, FACAAI

8:30 am – Kids Are Not Little Adults: Unique Aspects to Diagnosis and Treatment of Cough in Children
William C. Anderson, MD, FACAAI

9:00 am – The Future Is Bright: Hopeful Options for Asthma
Leonard B. Bacharier, MD, FACAAI

9:30 am – Adjourn

In this session, the attendee will be given an in-depth perspective on the outcomes and knowledge gained from the Australian HealthNuts prospective, population-based food allergy prevalence study at 10 years in terms of the development, risk factors for development and natural history of food allergy. In addition, this session will detail the next frontier in food allergy prevention from studies ongoing in the Center for Food Allergy Research consortium across Australia, detailing their work into early tree nut introduction and how vitamin D, maternal diet and vaccines may influence the development of food allergy in the infant. Lastly, the attendee will learn about cutting-edge ongoing research from Israel regarding tree nut oral immunotherapy and how desensitization to one tree nut can protect against multiple tree nut allergies.

All times listed are Central Standard Time (CST).

Moderators: Ruchi Gupta, MD, MPH, and Benjamin Prince, MD 

8:00 am – Welcome and Introductions
Ruchi Gupta, MD, MPH,  and Benjamin Prince, MD

8:05 am – The HealthNuts Study at Age 10: Lessons Learned and Future Directions
Jennifer Koplin, MD, PhD

8:30 am – Ahead of the Curve: The Next Wave of Strategies for Preventing Food Allergy
Kirsten Perret, MBBS, FRACP, PhD

8:55 am – One Nut, Two Nuts, Three Nuts, Four? Achieving Parsimony for Tree Nut Oral Immunotherapy
Arnon Elizur, MD

9:20 am – Questions and Discussion

9:30 am – Adjourn

Over the last few years, we have continued to learn more about how IL-5 and eosinophils often mediate severe asthma and other related conditions. However, our understanding is still incomplete. The ability to determine to what extent this pathway is responsible for asthma pathophysiology can still be challenging. Similarly, with multiple biologics available, it can be difficult for the asthma specialist to determine which specific agent is most appropriate and beneficial to the patient. Determining the most accurate and clinically meaningful biomarkers would be a major step in this process. With better understanding of the pathophysiology, and continuing education of asthma specialists, multiple healthcare benefits could be realized. Patient care and asthma control would improve maximally and most expeditiously with the best choice of biologic being made initially. This would help decrease healthcare dollars spent on exacerbations, ED visits, hospitalizations, as well as minimize patient job/school absenteeism.

All times listed are Central Standard Time (CST).

Moderators: Jeremy S. Katcher, MD, FACAAI, and Alan B. Goldsobel, MD, FACAAI

8:00 am – Welcome and Introductions
Jeremy S. Katcher, MD, FACAAI, and Alan B. Goldsobel, MD, FACAAI 

8:03 am – Subtypes of Severe Asthma With Emphasis on Eosinophilic Subtype
William C. Anderson, MD, FACAA

8:28 am – Biomarker Interpretations and How This Would Aid in Treatment Choice and Prognosis Prediction
Leonard B. Bacharier, MD, FACAAI 

8:53 am – IL-5/Eosinophil-related Conditions Other Than Severe Eosinophilic Asthma
Princess Ogbogu, MD, FACAAI

9:20 am – Questions and Discussion (Online Chat)

9:30 am – Adjourn

Non-IgE-mediated food intolerances and allergies are common concerns among patients. This session will address the current evidence and understanding of how to recognize the features pertaining to common conditions, decide what tests to utilize to assist diagnosis and review treatment options.

All times listed are Central Standard Time (CST).

Moderators: Anna H. Nowak-Wegrzyn, MD, FACAAI, and Irene Mikhail, MD

8:00 am – Welcome and Introductions
Anna H. Nowak-Wegrzyn, MD, FACAAI, and Irene Mikhail, MD

8:03 am – FPIES – Prevalence, Diagnosis and Management Pearls
Terri F. Brown-Whitehorn, MD

8:30 am – Eosinophilic Esophagitis
Antonella Cianferoni, MD

9:00 am – Allergic Proctocolitis and Other Crimes Against Humanity Attributed to Milk
J. Andrew Bird, MD, FACAAI

9:30 am– Adjourn

Not For Credit

The COVID-19 pandemic has revealed the importance of flexible approaches to caring for food-allergic patients, with potential implications for future treatment preferences. This symposium will include a discussion of the recent expert panel consensus document to guide decision-making in the allergy/immunology clinic, with a focus on food allergy care.

Presented by: Matthew Greenhawt, MD

Supported by DBV Technologies

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

A discussion about the rising rates of anaphylaxis and the role providers play to help reduce the risk that a child will develop certain food allergies by identifying high-risk patients and educating caregivers on the early introduction of allergens. Dr. Gupta and Dr. Mahr are paid advisors for kaléo, Inc.

Presented by: Ruchi Gupta, MD, and Todd Mahr, MD

Supported by by kaléo

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

While practicing in allergy, health care practitioners are often asked about a rash or other skin conditions. This session will improve their diagnosis and management skills for common skin conditions that may present in the allergy office.

Educational credit for the Advanced Practice Health Care Providers Course is only available to those who pre-registered for it.

All times listed are Central Standard Time (CST).

Moderator: Jodi A. Shroba, MSN, APRN, CPNP

10:00 am – Welcome and Introductions
Jodi A. Shroba, MSN, APRN, CPNP

10:03 am – Clinical Pearls From the Dermatologist 
Marc Serota, MD

10:45 am – Questions and Discussion (Online Chat)

11:00 am – Adjourn

The evidence shows that there are consequences of using oral corticosteroids (OCS) even in low doses. Overuse of OCS presents even more challenges up to, and including, mortality. Thus, there is a high cost involved in OCS overuse due to side effects. Even though biologics are expensive, they do offer an alternative to OCS. OCS overuse is relevant in GI and pulmonology as well as allergy.

All times listed are Central Standard Time (CST).

Moderators: ACAAI President J. Allen Meadows, MD, FACAAI, and WAO President Motohiro Ebisawa, MD

10:00 am – Welcome and Introductions
ACAAI President J. Allen Meadows, MD, FACAAI, and WAO President Motohiro Ebisawa, MD

10:03 am – Effects of Corticosteroids on Human Health
Eugene R. Bleecker, MD

10:30 am – Health Consequences of Overuse of Corticosteroids
Arnaud Bourdin, MD

11:00 am – Economic Impacts – Cost of Side Effects From Overuse of Corticosteroids
Giorgio Walter Canonica, MD

11:30 am – Adjourn

All times listed are Central Standard Time (CST).

Moderator: Kelly M. Maples, MD, FACAAI

10:00 am – Welcome and Introductions
Kelly M. Maples, MD, FACAAI

10:03 am – Changes in Utilization of Acute Medications After Initiation of Prophylactic Treatments for Hereditary Angioedema
Dawn Hyatt, PharmD

10:18 am – The Food Sensitization Related to A-896G Gene Polymorphism of TLR-4 in Adults With Atopic Dermatitis
Yuriy Bisyuk, MD

10:33 am – Friends Don’t Let Friends Mix Alone: Anaphylaxis in the Mixing Lab
Mike Tankersley, MD, MBA

10:48 am – Questions and Discussion (Online Chat)

11:30 am – Adjourn

All times listed are Central Standard Time (CST).

Moderators: John  J. Oppenheimer, MD, FACAAI, and Brian T. Kelly, MD, MA, FACAAI

10:00 am – Welcome and Introductions
John J. Oppenheimer, MD, FACAAI and Brian T. Kelly, MD, MA, FACAAI

10:03 am – It's a Unified Airway: Options for Sinus Disease
Anju T. Peters, MD

10:30 am – Current and Emerging Biologics in Atopic Dermatitis
Mark Boguniewicz, MD, FACAAI 

11:00 am – Beyond OIT: How Biologics Can Help Patients With Food Allergy
David M. Fleischer, MD, FACAAI

11:30 am – Adjourn

This program is designed to bring together academic allergy/immunology leaders, including department/division/section leaders, associate leaders and program directors, to hear about work that has been done by the task force and to provide additional input into the task force deliberations. The overall effort to is create a viable and energetic network of academic allergy/immunology leaders who can ensure that the profession survives and thrives in the changing academic environment.

All times listed are Central Standard Time (CST).

Moderators: Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD

10:00 am – Welcome and Introductions
Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD

10:03 am – Joint Task Force Update
Bryan L. Martin, DO, FACAAI

10:30 am – Increasing the Scope and Visibility of Your Academic Division
Aidan A. Long, MD

11:00 am – Overcoming Financial Issues in the Academic Allergy/Immunology Division
Kevin J. Kelly, MD, FACAAI

11:30 am – Adjourn

This workshop will focus on helping practicing allergists set up a telemedicine program in their office, as well as bill and get paid for providing the service. Attendees will also get tips on how to see patients using this technology.

All times listed are Central Standard Time (CST).

Moderators: Jay M. Portnoy, MD, FACAAI, and David M. Lang, MD, FACAAI

10:00 am – Welcome and Introductions
Jay M. Portnoy, MD, FACAAI,  and David M. Lang, MD, FACAAI

10:03 am – The Changing Paradigm of Telemedicine
Jennifer A. Shih, MD

10:30 am – How To Implement Telemedicine Into Your Practice
Tania Elliot, MD, FACAAI

10:55 am – Coding and Billing for Telemedicine Services: How To Get Started and How To Get Paid
Sakina S. Bajowala, MD 

11:20 am – Questions and Discussion

11:30 am – Adjourn

With the rise in prevalence of multiple childhood allergic diseases, schools have been forced to deal with management facets to ensure that students remain safe and healthy at school. As well, schools have represented opportunities to reach populations who may otherwise lack access to healthcare services to both diagnose and manage allergic diseases. This session will detail the approach to the care of managing the patient with allergic disease in the school setting and discuss challenges and opportunities of how to deliver care in school-based settings.

All times listed are Central Standard Time (CST).

Moderators: Bruce J. Lanser, MD, FACAAI, and Irene Mikhail, MD

10:00 am – Welcome and Introductions
Bruce J. Lanser, MD, FACAAI, and Irene Mikhail, MD

10:03 am – Improving the Health of Students: Successful Approaches to Community Partnerships With Schools
Michael Pistiner, MD, MMSc, FACAAI

10:30 am – Food Allergies and Anaphylaxis in Schools
Julie Wang, MD, FACAAI

10:55 am – Wheezing in the Classroom: School-based Asthma Management
Sujani Kakumanu, MD

11:20 am – Questions and Discussion

11:30 am – Adjourn

Not For Credit

Join us for an interactive presentation on a steroid-free topical therapy for the treatment of mildto- moderate atopic dermatitis. Expert faculty will guide the audience through an in-depth look into the product and answer questions to help attendees gain a better understanding of this treatment option.

Presented by: Adelaide A. Hebert, MD

Supported by Pfizer, Inc.

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

You are cordially invited to view a pre-recorded program to learn about the clinical impact of a targeted biologic treatment option on exacerbations, lung function, and reducing oral corticosteroids in patients with severe eosinophilic asthma. Listen to an expert to explore its clinical efficacy, mechanism of action and safety profile data.

Presented by: Katharine Woessner, MD

Supported by AstraZeneca

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

Please join us on November 14th at 11:35 am as Greg Bensch, MD presents Digihaler® Technology. Learn about the role of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder and AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder in clinical practice.

Presented by: Greg Bensch, MD

Supported by Teva Pharmaceuticals, Inc.

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Idiopathic anaphylaxis can be frustrating and challenging for both patients and clinicians. This session will explore the diagnosis and management of this condition along with the latest recommendations for management of anaphylaxis from any cause. Alpha-gal allergy is a delayed allergic reaction to the ingestion of mammalian meats which contains the sugar or carbohydrate alpha gal (glactose-alpha-1, 3-galactose). This allergy is triggered by a tick bite. This session will review the development and management of this tick-borne allergy.

Educational credit for the Advanced Practice Health Care Providers Course is only available to those who pre-registered for it.

All times listed are Central Standard Time (CST).

Moderator: Jodi A. Shroba, MSN, APRN, CPNP

1:00 pm – Welcome and Introductions
Jodi A. Shroba, MSN, APRN, CPNP

1:03 pm – Idiopathic Anaphylaxis and Updates on Anaphylaxis Management
Julie Wang, MD, FACAAI

1:45 pm – Just One Bite Can Cause a Food Allergy: A Review of Alpha-gal 
Scott Commins, MD, PhD

2:30 pm - Adjourn

The CAP Review is a literature-style review covering most of the articles chosen by the ABAI for the current six-month cycle of the Continuous Assessment Program (CAP). Each presenter will focus on key aspects of the study design, results and implications for practice. The goal of this session is to help prepare attendees for the first cycle of ABAI CAP program.

Due to the impacts of COVID-19 on physicians, ABAI has canceled Block 2 for 2020. The completion of the Block 1 Continuous Assessment Program has been extended to January 15, 2021.

All times listed are Central Standard Time (CST).

Moderator: Brian T. Kelly, MD, MA, FACAAI

1:00 pm – Welcome and Introductions
Brian T. Kelly, MD, MA, FACAAI

1:03 pm – Head/Neck
Jeremy Katcher, MD, FACAAI

1:30 pm  – Dermatologic
Kelly M. Maples, MD, FACAAI

2:00 pm – Lung/Food & Drug Allergy/Hypersensitivity Reactions
Brian T. Kelly, MD, MA, FACAAI

2:30 pm – Adjourn

All times listed are Central Standard Time (CST).

Moderator: J. Wesley Sublett, MD, MPH, FACAAI

1:00 pm – Welcome and Introductions
J. Wesley Sublett, MD, MPH, FACAAI

1:03 pm – Tezepelumab Efficacy in Severe Asthma by Specific Allergen Sensitivity: Results From the PATHWAY Study
Jonathan Corren, MD, FACAAI

1:18 pm – Eosinophilia (>300/ul) Marks Small Airway Obstruction Irrespective of Allergic Sensitization in Inner-city Severe Asthmatics
Granit Mavraj, MD

1:33 pm – Changes in Nasal Airflow With Loratadine-pseudoephedrine Versus Fluticasone Spray After First Dose for Allergy
Anne K. Ellis, MD, MSc, FACAAI

1:48 pm – Serum IL-6 Levels in Patients With Aspirin-exacerbated Respiratory Disease
Anuj Kapil, MD

2:03 pm – House Dust Mite Environmental Exposure Unit: Clinical Validation of a Model for Perennial Allergic Rhinitis
Lubnaa Hossenbaccus

2:18 pm – Questions and Discussion (Online Chat)

2:30 pm – Adjourn

Supported by an independent educational grant from Merck

All times listed are Central Standard Time (CST).

Moderators: Alan B. Goldsobel, MD, FACAAI, and David R. Stukus, MD, FACAAI

1:00 pm – Welcome and Introductions
Alan B. Goldsobel, MD, FACAAI, and David R. Stukus, MD, FACAAI

1:03 pm – How Our Understanding of Pathophysiology Has Evolved
Jaclyn Smith, MB, ChB, PhD

1:30 pm – Current Guideline-based Approaches to Treatment of Cough
Kaiser Lim, MD

1:55 pm – Insight Into New Treatment Paradigms
Peter Dicpinigaitis, MD

2:20 pm – Questions and Discussion

2:30 pm – Adjourn

According to recent data from the NIH and Natural Center for Health Statistics, approximately 38% of adults and 12% of children use some form of integrative medicine, while more than 60% of allergy sufferers try a natural product. This has significant impact on the traditional practice of medicine. There is a need to improve our recognition, understanding and treatment of integrative medicine (“complementary and alternative”) therapies in the field of allergy and immunology. This seminar is designed as an introductory course to educate allergy and immunology specialists on the most common integrative medicine therapies being used in our field.

All times listed are Central Standard Time (CST).

Moderator: William S. Silvers, MD, FACAAI, and Payel Gupta, MD, FACAAI

1:00 pm – Welcome and Introductions
William S. Silvers, MD, FACAAI, and Payel Gupta, MD, FACAAI

1:03 pm – Bringing It Into Your Practice
Anil Nanda, MD, FACAAI 

1:30 – Practical Tips
Dipa K. Sheth, MD, FACAAI

1:55 pm – What Does the Evidence Support?
Gary K. Soffer, MD

2:20 pm – Questions and Discussion (Online Chat)

2:30 pm – Adjourn

This session is designed to assist the attendee in developing a better understanding of terms used to diagnose various skin conditions, recognize common and similar patterns of skin disease and formulate a treatment strategy. Rapid fire, high yield and fun, all rolled into one.

All times listed are Central Standard Time (CST).

Host: Stephanie L. Mawhirt, DO

Faculty: Kelly M. Maples, MD, FACAAI; Luz S. Fonacier, MD, FACAAI, and James Treat, MD

1:00 pm – Welcome and Introductions
Stephanie L. Mawhirt, DO

1:05 pm – Game Time!

2:20 pm – Questions and Discussion

2:30 pm – Adjourn

Not For Credit

Hypereosinophilic syndrome (HES) is a rare and debilitating multi-system disorder characterized by elevated eosinophil levels in blood and/or tissues with organ damage/dysfunction that occurs without evidence of secondary causes of hypereosinophilia. Multiple organ involvement results in highly variable clinical manifestations. This brief presentation will provide a summary of current understanding.

Presented by: David Bernstein, MD

Supported by GSK

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

There is mounting evidence that children with allergic conditions – including food allergy, eosinophilic esophagitis (EoE), and atopic dermatitis – and their families experience psychosocial stressors such as poor quality of life, stress, anxiety, depression, social challenges including bullying and low self-esteem. When examined individually, unique challenges are noted for each allergic condition due to the nature of the condition’s presentation and treatment regimen. The presenters will describe the psychological intervention services they provide and how mental health professionals are integrated into clinics that treat these populations.

Educational credit for the Advanced Practice Health Care Providers Course is only available to those who pre-registered for it.

All times listed are Central Standard Time (CST).

Moderator: Jodi A. Shroba, MSN, APRN, CPNP

3:00 pm – Welcome and Introductions
Jodi A. Shroba, MSN, APRN, CPNP

3:03 pm – The Clinical Role of Psychology in Food Allergy
Ashley Ramos, PhD

3:25 pm – Psychosocial Challenges in Pediatric Eosinophilic Esophagitis
Ashley Kroon Van Diest, PhD

3:50 pm – Assessing  Emotional and Behavioral Health in Children and Adults With Atopic Dermatitis
Jennifer Darr, MSW, LCSW

4:15 pm – Questions and Discussion (Online Chat)

4:30 pm – Adjourn

The CAP Review is a literature-style review covering most of the articles chosen by the ABAI for the current six-month cycle of the Continuous Assessment Program (CAP). Each presenter will focus on key aspects of the study design, results and implications for practice. The goal of this session is to help prepare attendees for the first cycle of ABAI CAP program.

Due to the impacts of COVID-19 on physicians, ABAI has canceled Block 2 for 2020. The completion of the Block 1 Continuous Assessment Program has been extended to January 15, 2021.

All times listed are Central Standard Time (CST).

Moderator: Brian T. Kelly, MD, MA, FACAAI

3:00 pm – Welcome and Introductions
Brian T. Kelly, MD, MA, FACAAI

3:03 pm – Anaphylaxis
Anne K. Ellis, MD, MSc, FACAAI

3:25 pm – Immune Hypersensitivity Disorders
Nikita Raje, MD, FACAAI

3:50 pm – Immunodeficiencies
Benjamin Prince, MD

4:10 pm – Eosinophilic or Gastrointestinal Disorders
Gerald B. Lee, MD

4:30 pm – Adjourn

This session will highlight several of the best articles published in Annals. The current Editor-in-Chief of Annals, Gailen Marshall, MD, and Editor-in-Chief Elect, Mitchell Grayson, MD, will provide insight regarding the impact and clinical application of various articles pertaining to allergy and immunology.

Moderator: John J. Oppenheimer, MD, FACAAI

Speakers: Gailen D. Marshall, MD, PhD, FACAAI, and Mitchell H. Grayson, MD, FACAAI 

During the ACAAI FIT Section’s annual business meeting, attendees will receive an update on the Section’s activities and elect its next Junior FIT Representative to the Board of Regents.

The one-hour educational program following the business meeting will be a career panel. Attendees hear from three established allergists who will share real-world perspectives on careers in private practice, academics and government. The panelists will discuss how to best prepare for and succeed in the first few years in a new position, as well as how to lay the groundwork for a successful career in each of the three areas.

All times listed are Central Standard Time (CST).

Moderators: Miriam Samstein, MD, and Timothy Chow, MD

3:00 pm – Welcome and Introductions
Miriam Samstein, MD, and Timothy Chow, MD

3:05 pm – Junior FIT Representative Candidate Speeches & Voting

3:30 pm – Career Panel
Angela Hogan,  MD, FACAAI, Anil Nanda, MD, FACAAI, Stephen Tilles, MD, FACAAI

4:25 pm – Announcement of 2020-2021 Junior FIT Representative and Closing Remarks

4:30 pm – Adjourn

All times listed are Central Standard Time (CST).

Moderator: Gerald B. Lee, MD

3:00 pm – Welcome and Introductions
Gerald B. Lee, MD

3:03 pm – Decoding Allergic Poly-sensitization with Machine Learning
Brian Patchett

3:18 pm – The Role of Aeroallergens in the Pathogenesis of Eosinophilic Esophagitis: Is There a Relationship?
Talal Nsouli, MD

3:33 pm – Specific Peanut Epitopes as a Biomarker for Desensitization During Epicutaneous Immunotherapy
David M. Fleischer, MD, FACAAI

3:48 pm – Dietary Access and Behaviors Among Food Allergic Black and White Children in the FORWARD Study
Amaziah Coleman, MD

4:03 pm – Questions and Discussion (Online Chat)

4:30 pm – Adjourn

All times listed are Central Standard Time (CST).

Moderators: John J. Oppenheimer, MD, FACAAI, and Brian T. Kelly, MD, MA, FACAAI

3:00 pm – Welcome and Introductions
John J. Oppenheimer, MD, FACAAI and Brian T. Kelly, MD, MA, FACAAI

3:03 pm – Navigating Current Asthma Choices
Thomas B. Casale, MD, FACAAI

3:45 pm – Cost-effectiveness of Biologics
Stanley J. Szefler, MD, FACAAI

4:20 pm – Questions and Discussion

4:30 pm – Adjourn

The concept of allergenic thresholds remains elusive and controversial. While there is evidence that these exist, there is also uncertainty in how these can be established and regulated and how they may vary at a patient level. Understanding of thresholds has broad social and medico-legal impact with respect to how patients are being managed and how products are labeled at stores and in restaurants.

All times listed are Central Standard Time (CST).

Moderators: Douglas P. Mack, MD, MSc, and Brian T. Kelly, MD, MA, FACAAI

3:00 pm – Welcome and Introductions
Douglas P. Mack, MD, MSc, and Brian T. Kelly, MD, MA, FACAAI

3:03 pm – Understanding Variability in Threshold Response
Andrew Clark, MD

3:30 pm – Understanding the Regulatory Climate for Threshold Labeling
Stefano Luccioli, MD

4:00 pm – The Australian Experience Regarding VITAL
Jennifer Koplin, MD, PhD

4:30 pm – Adjourn

The management of chronic urticaria has evolved in recent years, but several mainstays can continue to offer benefit. This session will review the evidence surrounding older approaches, current approaches and what potential treatment options may be available. The important aspect of helping patients beyond medication and addressing the significant psychosocial impact of refractory chronic urticaria will also be addressed.

All times listed are Central Standard Time (CST).

Moderators: Kelly M. Maples, MD, FACAAI, and Joseph P. Forester, DO, FACAAI

3:00 pm – Welcome and Introductions
Kelly M. Maples, MD, FACAAI, and Joseph P. Forester, DO, FACAAI

3:03 pm – Omalizumab for Antihistamine-refractory Urticaria
Sarbjit S. Saini, MD

3:25 pm – Emerging Therapies for Refractory Urticaria
David A. Khan, MD, FACAAI

3:50 pm – Evidence for Other Biologics in Refractory Urticaria
Marc Serota, MD

4:15 pm – Questions and Discussion (Online Chat)

4:30 pm – Adjourn

Supported by DBV Technologies  

Test your knowledge, sharpen your wits and join in the fun at this year’s virtual FIT Bowl! Watch participating teams from training programs around the country compete to answer a variety of serious (and not so serious) questions posed by an expert panel. This year, 19 teams competed in preliminary rounds and 4 sets of finalists will complete for the coveted FIT Bowl trophy.

Not For Credit

Join us to discuss real-world evidence updates on the relationships of asthma control, patient behaviors and SABA reliance as we focus on the unmet need in asthma patients who may be at risk for exacerbations. Learn how PRECISION may help improve the identification and management of patients with uncontrolled asthma.

Presented by: Bradley Chipps, MD; Miguel Lanz, MD; and Kevin Murphy, MD

Supported by AstraZeneca

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

This presentation provides an in-depth look at a proven innovation to neutralize Fel d 1, the major cat allergen, at its source. As part of a comprehensive allergen management program, this approach is safe for the cat and helps keep the cat in the home.

Presented by: Ebenezer Satyaraj, PhD

Supported by Purina Institute

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

Uncontrolled asthma continues to burden patients, care teams, and healthcare systems. Medical experts will provide insight into the challenges of coping with uncontrolled asthma, review the current treatment paradigms, and identify ways to customize management of uncontrolled asthma by pairing the right medications with the right patients.

Presented by: John Oppenheimer, MD, and Angela Hogan, MD

Supported by GSK

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

This session will discuss the diagnosis and management of atopic dermatitis. It will also discuss the role that allied health professionals play in providing emotional support, formal and systematic education and individualized practical advice that contributes to improved treatment adherence and can enhance the quality of life for patients and their families throughout the course of an often-prolonged disease.

Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

Supported by an independent educational grant from Aimmune Therapeutics

All times listed are Central Standard Time (CST).

Moderator: Abby L. Allen, RN, NP

8:00 am – Welcome and Introductions
Abby L. Allen, RN, NP

8:03 am – The Role of the Nurse in the Care and Management of Patients With Atopic Dermatitis
Sally Schoessler, MSEd, BSN, RN, AE-C

8:45 am – Adjourn
 

ACAAI is pleased to present our Clemens von Pirquet Recipients for the 2020 Annual Meeting.

All times listed are Central Standard Time (CST).

Moderator: Brian T. Kelly, MD, MA, FACAAI

8:00 am – Welcome and Introductions
Brian T. Kelly, MD, MA, FACAAI

8:03 am – Clemens von Pirquet - 1st Place Award: Pulse Oximetry and Centile-based Vital Signs Predict Hospital Length of Stay in Pediatric Asthma Exacerbation
Jose Rojas Camayo, MD

8:18 am – Clemens von Pirquet - 2nd Place Award: Clinical Impact of Reported Non-steroidal Anti-inflammatory Drug Allergies in Patients With Osteoarthritis
Lily Li, MD

8:33 am – Clemens von Pirquet - 3rd Place Award: Characterizing Asthma Among Adults With Primary Antibody Deficiencies: Results From a Nationwide Patient Survey
Deepti Deshpande, MD

8:48 am – Questions and Discussions (Online Chat)

9:00 am – Adjourn

The ACAAI, ABAI and diplomates are key stakeholders in the current transformation of Allergy and Immunology Continuing Certification. This session will provide attendees with an overview of the current landscape of continuing board certification, an update of the continuous certification assessment program (CAP) and the personal progress meter. An interactive town hall will be held during this session as part of ABAI's commitment to co-development of specialty continuing certification.

Moderators: Michael R. Nelson, MD, PhD, FACAAI, and Kathleen May, MD, FACAAI

8:00 am – Welcome and Introductions
Michael R. Nelson, MD, PhD, FACAAI, and Kathleen May, MD, FACAAI

8:03 am – Provide Understanding of Continuous Assessment Program (CAP)
Michael R. Nelson, MD, PhD

8:18 am – Understand the ABMS, ABAI Vision Commission and What It Means to You
Michael R. Nelson, MD, PhD

8:23 am – Understand Use of Diplomate Progress Meter
Kathleen May, MD, FACAAI

8:30 am – Town Hall Questions and Discussion (Online Chat)
Michael R. Nelson, MD, PhD, FACAAI; Kathleen May, MD, FACAAI; Ted Freeman, MD, FACAAI; Rayne Harrison; and Cecilia MacCormack

9:00 am – Adjourn

This plenary will include high-yield practical information from four major updates to clinical guidelines and practice parameters. Each speaker was intimately involved in the development of each guideline and can offer unmatched perspective. This is a can't-miss session applicable to all meeting attendees.

All times listed are Central Standard Time (CST).

Moderator: Todd A. Mahr, MD, FACAAI

8:00 am – Welcome and Introductions
Todd A. Mahr, MD, FACAAI

8:03 am – Practice Parameter – Rhinitis
Mark S. Dykewicz, MD, FACAAI

8:30 am – Practice Parameter – Anaphylaxis
Marcus S. Shaker, MD, FACAAI

8:55 – Practice Parameter – Diagnostic Testing for Peanut Allergy
Matthew C. Greenhawt, MD, MBA, MSc, FACAAI

9:20 am – Questions and Discussion

9:30 am – Adjourn

Conditions impacting the skin can change dramatically in patients with different backgrounds. This session will review special populations and how evaluation and treatment of dermatitis can be tailored based on physiologic, socioeconomic and psychosocial differences.

All times listed are Central Standard Time (CST).

Moderators: Ira Finegold, MD, FACAAI, and Ellen R. Sher, MD, FACAAI 

8:00 am – Welcome and Introductions
Ira Finegold, MD, FACAAI, and Ellen R. Sher, MD, FACAAI

8:03 am – Itch and Dermatitis in the Elderly
David R. Weldon, MD, FACAAI

8:30 am – Dermatitis in Skin of Color
Andrew Alexis, MD, MPH

8:55 am – Occupational Dermatitis
Karin A. Pacheco, MD, MSPH

9:20 am – Questions and Discussion (Online Chat)

9:30 am – Adjourn

To help you stay abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful literature review program. It’s a review of the most important, clinically-focused literature of our specialty published between November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice.

The Literature Review Program is only available to those who pre-registered for it.

All times listed are Central Standard Time (CST).

Moderator: James T. Li, MD, PhD, FACAAI

8:00 AM – Welcome and Introductions
James T. Li, MD, PhD, FACAAI

8:03 AM – Basic Immunology
Mitchell H. Grayson, MD, FACAAI

8:30 AM – Rhinitis and Sinusitis
Anju T. Peters, MD

9:00 AM – Update in Clinical Immunology
John M. Routes, MD, FACAAI

9:30 AM– Adjourn

Presently, there are two delivery options for immunotherapy available to treat respiratory allergy. Many allergists have difficulty in determining the optimal therapy for their patients.

All times listed are Central Standard Time (CST).

Moderators: Myron J. Zitt, MD, FACAAI, and Stanley M. Fineman, MD, MBA, FACAAI

8:00 am – Welcome and Introductions
Myron J. Zitt, MD, FACAAI, and Stanley M. Fineman, MD, MBA, FACAAI

8:03 am – SCIT Is the Answer
David I. Bernstein, MD, FACAAI

8:30 am – SLIT Is the Answer
Peter S. Creticos, MD

8:55 am – No One Option Is Perfect – A Role for Shared Decision-making
Desiree E. Larenas-Linnemann, FACAAI

9:20 am – Questions and Discussion

9:30 am – Adjourn

Food allergies and other allergic conditions can have a significant impact on quality of life, both medically and psychosocially. Therefore, a collaborative care model that includes partnering with allied healthcare professionals can result in more robust patient care. Participants will be given information on multiple allied healthcare fields, as well as the benefits, methods and logistics of partnering with these providers.

Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

Supported by an independent educational grant from Aimmune Therapeutics

All times listed are Central Standard Time (CST).

Moderator: Abby L. Allen, RN, NP

10:00 am – Welcome and Introductions
Abby L. Allen, RN, NP

10:03 am – Let’s Work Together: Collaborative Patient Care Models in Community Allergy Practices
J. Wesley Sublett, MD, MPH, FACAAI; Raquel Durban, MS, RD, CSP, LDN; and Linda Herbert, PhD

11:30 am – Adjourn

The EAACI Symposium is dedicated to allergen immunotherapy as an essential tool for achieving long-term control of allergic diseases and asthma.

All times listed are Central Standard Time (CST).

Moderators: J. Allen Meadows, MD, FACAAI, and Marek Jutel, MD, PhD 

10:00 am – Welcome and Introductions
J. Allen Meadows, MD, FACAAI, and Marek Jutel, MD, PhD

10:03 am – Barriers and Facilitators in Research and Clinical Practice
Stefano del Giacco, MD, PhD

10:30 am – AIT for Allergic Asthma – Controversies and Solutions
Ioana O. Agache, MD, PhD

11:00 am – Bridging the Gap: Innovative Methodology for AIT Trials
Marek Jutel, MD, PhD

11:30 am – Adjourn

All times listed are Central Standard Time (CST).

Moderator: Melanie A. Ruffner, MD, PhD

10:00 am – Welcome and Introductions
Melanie A. Ruffner, MD, PhD

10:03 am – Inner-city Asthma Telemedicine During COVID Pandemic
Kenny Kwong, MD

10:18 am – Long-term Efficacy of a Video Module on Resident and Medical Student Understanding of Penicillin Allergy
Kavitha Thiagarajan, MD

10:33 am – The Impact of COVID-19 and Disease Control Measures on Pediatric Food Allergy Parents/Caregivers and Patients
Christopher Warren, MD

10:48 am – A Quality Improvement Project on Pediatric Resident Knowledge of Primary Immunodeficiency
Yatyng Chang, MD

11:03 am – Expanding Penicillin Allergy Evaluation for Prenatal Patients
Lulu Tsao, MD

11:18 am – Questions and Discussion (Online Chat)

11:30 am – Adjourn

The more we learn about asthma, the more we know it is not a "one size fits all" condition. This session will review special populations and how their asthma care can be tailored based on physiologic, socioeconomic, and psychosocial differences.

Supported in part by an independent educational grant from AstraZeneca

All times listed are Central Standard Time (CST).

Moderators: Jeremy S. Katcher, MD, FACAAI, and Jared Darveaux, MD

10:00 am – Welcome and Introductions
Jeremy S. Katcher, MD, FACAAI, and Jared Darveaux, MD

10:03 am – Impact of Hormones and Pregnancy on Asthma and Allergies
Jennifer Namazy, MD

10:30 am – Asthma, Rhinitis and Allergic Skin Disease in Older Adults
Tolly E. Epstein, MD, MS, FACAAI

10:55 am – Racial and Ethnic Disparities in Asthma and Allergic Disease
Andrea J. Apter, MD, FACAAI 

11:20 am – Questions and Discussion

11:30 am – Adjourn

This session will address relevant changes, modifications and implementation of CPT and ICD-10 coding for 2020. This will be accomplished by practical case-based scenarios focused on how the change may affect the practice of allergy and clinical immunology. In addition, we’ll review the state of politics and the national perspective of medicine as seen through the eyes of the AMA. Finally, we’ll offer an update on the changing landscape on Capitol Hill as it relates to the current state of government.

All times listed are Central Standard Time (CST).

Moderators: James Sublett, MD, FACAAI, and Warner W. Carr, MD, FACAAI

10:00 am – Welcome and Introductions
James L. Sublett, MD, FACAAI, and Warner W. Carr, MD, FACAAI

10:03 am – Coding Update
Gary N. Gross, MD, FACAAI

10:28 am – The Importance of the Physician Advocate
James M. Tracy, DO, FACAAI

10:53 am – Government/Legislative Update
Bill Finerfrock, President, Capitol Associates; Consultant, Advocacy Council of ACAAI

11:20 am – Questions and Discussion

11:30 am – Adjourn

The use of medical marijuana and its derivatives, electronic cigarettes, and alternative nicotine delivery systems is on the rise, yet the risks and health benefits remain largely unclear. Furthermore, recent literature suggests that some of the more popular routes of administration, including vaping and hookah, can have deleterious health effects. Due to a rise in use across various ages, allergy and immunology specialists need to understand how these agents are being used and incorporate discussion of them into patient visits.

All times listed are Central Standard Time (CST).

Moderators: Ojas P. Patel, MD, FACAAI, and Andrew Nickels, MD, FACAAI

10:00 am – Welcome and Introductions
Ojas P. Patel, MD, FACAAI, and Andrew Nickels, MD, FACAAI

10:03 am – Making Sense of the Different Terminology and Delivery Systems
William S. Silvers, MD, FACAAI

10:30 am – Risks, Benefits and Adverse Effects: What Does the Evidence Show?
Rohit K. Katial, MD, FACAAI

10:55 am – How To Effectively Discuss Use With Adolescent Patients
Kevin R. Murphy, MD, FACAAI 

11:20 am – Questions and Discussion (Online Chat)

11:30 am – Adjourn

To help you stay abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful literature review program. It’s a review of the most important, clinically-focused literature of our specialty published between November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice.

The Literature Review Program is only available to those who pre-registered for it.

All times listed are Central Standard Time (CST).

Moderator: James T. Li, MD, PhD, FACAAI

10:00 am – Welcome and Introductions
James T. Li, MD, PhD, FACAAI

10:03 am – Asthma and Lower Respiratory Diseases
James T. Li, MD, PhD, FACAAI

10:30 am – Update on Skin Diseases, Urticaria, Angioedema and Other Skin Disorders
Marc A. Riedl, MD, MS

11:00 am – Update in Pediatric Allergy
John M. Kelso, MD, FACAAI

11:30 am – Adjourn

Not For Credit

This expert-led event will include a review and discussion of clinical and real-world data evaluating a biologic treatment to help reduce exacerbations and maintenance OCS use, as well as long-term clinical efficacy and safety data associated with the product.

Presented by: Jacqueline Eghrari-Sabet, MD

Supported by GSK

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

During this presentation, Dr. Clore will review the disease state and burden of atopic dermatitis (AD), discuss the integral components in the pathophysiology of AD, and describe the role of the JAK/STAT pathway in AD.

Presented by: Lee S. Clore, Jr, MD

Supported by by Pfizer, Inc.

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Not For Credit

Join us for a presentation that will provide an overview of eosinophilic immune dysfunction, which can be characterized as the dysregulation of biological mechanisms involved with eosinophil recruitment and activation that is seen across a range of diseases.

Presented by: Rohit Katial, MD

Supported by AstraZeneca

These non-CME commercial presentations and promotional sessions are organized by industry and designed to enhance your meeting experience. All attendees are invited to attend these sessions.

Industry programs will remain viewable on demand through February 6, 2021 following the Annual Meeting.

Oral challenges are an essential part of food allergy management. This session will review how to successfully perform oral challenges in the office and how to integrate the updated guidelines into your practice.

Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

Supported by an independent educational grant from Aimmune Therapeutics

All times listed are Central Standard Time (CST).

Moderator: Abby L. Allen, RN, NP

1:00 pm – Welcome and Introductions
Abby L. Allen, RN, NP

1:03 pm – Oral Food Challenge Update
J. Andrew Bird, MD, FACAAI

1:25 pm – In-office Challenges: Conducting Oral Food Challenges
Maria Crain, APRN, CPNP

1:50 PM – Oral Challenge Updates: Considerations From a Dietitian
Raquel Durban, MS, RD, CSP, LDN

2:15 pm – Questions and Discussion (Online Chat)

2:30 pm – Adjourn

All times listed are Central Standard Time (CST).

Moderator: Aikaterini Anagnostou, MD, PhD, FACAAI

1:00 pm – Welcome and Introductions
Aikaterini Anagnostou, MD, PhD, FACAAI

1:03 pm – Phenotypic Differences in Allergy to Multiple Foods Within a Cohort of Black and White Children
Christopher Warren, PhD

1:18 pm – Race/Ethnicity and Socioeconomic Status Effect on Food Allergy-related Quality of Life in Children and Caregivers
Christine Rubeiz, MD

1:33 pm – Tree Nut Graded Oral Food Challenge Outcomes in a Pediatric Tertiary Care Center
Melissa Anderson, MD

1:48 pm – Barriers to Oral Food Challenges: A Qualitative Analysis of the Caregiver Perspective
Natasha Correa, MD

2:03 pm – Food Allergy-related Bullying and School Policy Among Black and White Children in the FORWARD Study
Dannielle Brown, MD

2:18 pm – Questions and Discussion (Online Chat)

2:30 pm – Adjourn

A targeted look deep down the rabbit hole of biases, conspiracies and echo chambers during the COVID-19 pandemic.

All times listed are Central Standard Time (CST).

Moderator: Brian T. Kelly, MD, MA, FACAAI

1:00 pm – Welcome and Introduction
Brian T. Kelly, MD, MA, FACAAI

1:03 pm – The Influence of Social Media on Patients and Medical Decision-making  
David R. Stukus, MD, FACAAI

2:03 pm – Questions and Discussion (Online Chat)

2:30 pm – Adjourn

To help you stay abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful literature review program. It’s a review of the most important, clinically-focused literature of our specialty published between November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice.

The Literature Review Program is only available to those who pre-registered for it.

All times listed are Central Standard Time (CST).

Moderator: David A. Khan, MD, FACAAI

1:00 pm – Welcome and Introductions
David A. Khan, MD, FACAAI

1:03 pm – Anaphylaxis and Stinging Insect Hypersensitivity
Anne K. Ellis, MD, MSc, FACAAI

1:30 pm – Immunotherapy
Harold S. Nelson, MD, FACAAI

2:00 pm – Food Allergy
Matthew C. Greenhawt, MD, MSc, MBA, FACAAI

2:30 pm– Adjourn

Allergists/immunologists often see referrals for evaluation of patients who have a clinical history and/or laboratory results that overlap between allergies and other systemic conditions. This session will offer practical tips on how to navigate the differential diagnosis and evaluation of patients who lack clear diagnoses.

All times listed are Central Standard Time (CST).

Moderators: Eric Yen, MD, and Melanie A. Ruffner, MD, PhD

1:00 pm – Welcome and Introductions
Eric Yen, MD, and Melanie A. Ruffner, MD, PhD

1:03 pm – Elevated Total IgE Levels: What Can It Mean and When To Worry?
Alexandra Freeman, MD

1:30 pm – Evaluating a Patient With Elevated Peripheral Eosinophilia
Princess Ogbogu, MD, FACAAI

1:55 pm – Autoimmune and Inflammatory Mimickers
Jennifer R. Heimall, MD

2:20 pm – Questions and Discussion

2:30 pm – Adjourn

In the wake of the multiple early introduction trials and a host of international guidelines and meta-analyses that have been published in the past 5 years, the three North American allergy societies have jointly developed a set of comprehensive recommendations outlining an approach to the prevention of IgE-mediated food allergy, which update the respective society recommendations that predated these new developments. This session will inform the clinician regarding the new developments and the recommended evidence-based approach that balances both cutting-edge scientific advances and practical implementation of these recommendations.

All times listed are Central Standard Time (CST).

Moderators: Susan Waserman, MD, FACAAI, and Aikaterini Anagnostou, MD, PhD, FACAAI

1:00 pm – Welcome and Introductions
Susan Waserman, MD, FACAAI, and Aikaterini Anagnostou, MD, PhD, FACAAI

1:03 pm – What's New? Changes and Updates in Prevention Recommendations
Elissa M. Abrams, MD

1:30 pm – Policy Implications of the Updated Recommendations
Marcus S. Shaker, MD, MSc, FACAAI

1:55 pm – Lessons Learned From Widespread Implementation of Prevention Guidelines
Kirsten Perrett, MD

2:20 pm – Questions and Discussion

2:30 pm – Adjourn

This session will review how to differentiate IgE from non-IgE food conditions with appropriate testing. Once a diagnosis has been formulated, this session will review management of the condition, including the implementation of nutritional recommendations.

Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

Supported by an independent educational grant from Aimmune Therapeutics

All times listed are Central Standard Time (CST).

Moderator: Abby L. Allen, RN, NP

3:00 pm – Welcome and Introductions
Abby L. Allen, RN, NP

3:03 pm – Food Allergy Mimickers: Non-IgE Food Intolerances
Ashlee Law, PA-C

3:25 pm – Food Allergy Mimickers: A Dietitian’s Vantage Point
Raquel Durban, MS, RD, CSP, LDN

3:50 pm – Food Allergy Mimickers: Non-IgE Food Intolerances
Abby L. Allen, RN, NP

4:15 pm – Questions and Discussion (Online Chat)

4:30 pm – Adjourn

To help you stay abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful literature review program. It’s a review of the most important, clinically-focused literature of our specialty published between November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice.

The Literature Review Program is only available to those who pre-registered for it.

All times listed are Central Standard Time (CST).

Moderator: David A. Khan, MD, FACAAI

3:00 pm – Welcome and Introductions
David A. Khan, MD, FACAAI

3:03 pm – Occupational and Environmental Allergy
Mark S. Dykewicz, MD, FACAAI

3:30 pm – Drug Allergy
Aleena Banerji, MD

4:00 pm – The Year's Best Articles
David A. Khan, MD, FACAAI

4:30 pm – Adjourn

The updated 2019 GINA Guidelines represent a major shift in the strategy of treating mild asthma. Though there is potential long-term benefit to the patient, there are challenges in the adoption of these guidelines. This session will review the benefits and challenges of these guidelines in the context of patient care, provider adherence, the pharmaceutical industry and regulatory (FDA) issues.

All times listed are Central Standard Time (CST).

Moderators: James M. Quinn, MD, FACAAI, and Anthony J. Bonitatibus, MD

3:00 pm – Welcome and Introductions
James M. Quinn, MD, FACAAI, and Anthony J. Bonitatibus, MD

3:03 pm – Where Do They Overlap?
Jonathan A. Bernstein, MD, FACAAI

3:30 pm – Where Do They Differ?
Angela D. Hogan, MD, FACAAI

3:55 pm – What Are They Both Missing?
Leonard B. Bacharier, MD, FACAAI

4:20 pm – Questions and Discussion

4:30 pm – Adjourn

Hereditary angioedema (HAE) remains a condition with significant morbidity. In recent years, multiple new therapeutic options have been developed, with additional ones in the pipeline. This session will compare the WAO HAE guidelines with the US HAE guidelines and differentiate between intravenous C1 inhibitor, subcutaneous C1 inhibitor and the monoclonal antibody lanadelumab. In addition, future therapeutic options for HAE will be reviewed.

All times listed are Central Standard Time (CST).

Moderators: William R. Lumry, MD, FACAAI, and Amar Dixit, MD

3:00 pm – Welcome and Introductions
William R. Lumry, MD, FACAAI, and Amar Dixit, MD

3:03 pm – Comparing WAO Hereditary Angioedema and US Hereditary Angioedema Guidelines
Timothy J. Craig, DO, FACAAI

3:30 pm – How To Choose From the Current Therapies
Aleena Banerji, MD

3:55 pm – What Does the Future Hold for Hereditary Angioedema Therapy?
Marc A. Riedl, MD, MS

4:20 pm – Questions and Discussion (Online Chat)

4:30 pm – Adjourn

The microbiome is a hot topic and evidence surrounding its association with various allergic conditions is rapidly accumulating. This session will review the supportive evidence, practical approaches we can take now with our patients and unanswered questions that surround how the microbiome impacts common allergic conditions.

All times listed are Central Standard Time (CST).

Moderators: Christina E. Ciaccio, MD, MSc, FACAAI, and Mitchell H. Grayson, MD, FACAAI

3:00 pm – Welcome and Introductions
Christina E. Ciaccio, MD, MSc, FACAAI, and Mitchell H. Grayson, MD, FACAAI

3:03 pm – The Impact of the Microbiome on Atopic Dermatitis
Richard Gallo, MD

3:30 pm – Respiratory Microbiome and Its Effect on Asthma
Christina E. Ciaccio, MD, MSc, FACAAI

4:00 pm – Alterations in the Microbiome in Patients With Food Allergies
Carina Venter, PhD, RD

4:30 pm – Adjourn

Treatment of the inflamed eye can present significant challenges in the clinical setting, especially when multiple conditions may be present at the same time. Current scientific information about the pathophysiology, diagnosis and management of dry eye syndrome and allergic eye conditions will be presented. The attendees will subsequently be empowered to improve patient outcomes.

All times listed are Central Standard Time (CST).

Moderators: Jonathan M. Rodrigues, MD, FACAAI, and Purvi S. Parikh, MD, FACAAI

3:00 pm – Welcome and Introductions
Jonathan M. Rodrigues, MD, FACAAI, and Purvi S. Parikh, MD, FACAAI

3:03 pm – Pathophysiology of Dry Eye Syndrome and Allergic Ocular Conditions
Merin E. Kuruvilla, MD

3:30 pm – Diagnostic Evaluation of the Inflamed Eye
Guillermo Amescua, MD

3:55 pm – Treatment of Dry Eye Syndrome and Allergic Ocular Conditions
Leonard Bielory, MD, FACAAI

4:20 pm – Questions and Discussion

4:30 pm – Adjourn